For Movember, the month dedicated to men’s health, Public Open University Čakovec has created MO-DEFENDER, an online game for men aged 40 and over and their families. Across five stages, the game takes on common myths about prostate cancer. It is free and available in Croatian and English at https://pou-cakovec.hr/movember/

Why a game about prostate cancer

In the European Union, prostate cancer is the most common cancer in men, with more than 330,000 new diagnoses every year. Early prostate cancer usually has no symptoms, yet many men put off talking to their doctor: they wait for symptoms, feel embarrassed, or believe common myths about the tests. In MO-DEFENDER, these excuses become the opponents, and after each stage they are replaced with verified facts.

How the game works

Players pilot the MO-DEFENDER spaceship and, at each stage, face a boss that repeats a widespread myth. Every hit charges the Blue awareness ribbon, and each win opens a card with a short explanation and a link to a European source. The game runs in a web browser on a computer, tablet or phone, with nothing to install and no registration, and the ship is steered with the keyboard, mouse or touch.

Five myths and what the evidence says

  • Myth: “I feel fine, so there is no reason to get checked.”
  • Fact: early prostate cancer usually has no symptoms, so the time to talk to a doctor about checks is before anything feels wrong.
  • Myth: “Prostate cancer is an old man’s disease.”
  • Fact: prostate cancer is uncommon in your 40s, but this is the time to learn your risk. European guidelines advise offering a PSA test from 50, from 45 if a close relative was diagnosed before 60 or for men of African descent, and from 40 for carriers of a BRCA2 gene change.
  • Myth: “They will send you straight for a biopsy.”
  • Fact: checking usually starts with a PSA blood test, followed by an MRI scan if needed, which often helps avoid an unnecessary biopsy.
  • Myth: “Any diagnosis means immediate surgery and losing your sex life.”
  • Fact: low-risk tumours can often be safely monitored with active surveillance, and treatment starts if tests show the cancer is changing.
  • Myth: “Finding it early does not change the outcome.”
  • Fact: in the large European ERSPC trial, deaths from prostate cancer over 23 years were 13% lower among men aged 55 to 69 who were invited to regular PSA testing.

Verified sources

Every claim in the game has been checked against European expert sources, and each fact card links to its source: the European Association of Urology (EAU) guidelines, the European Society for Medical Oncology (ESMO) patient guide, the 2022 EU Council Recommendation on cancer screening, materials from Europa Uomo, the European prostate cancer patient coalition, and the ERSPC trial results published in The New England Journal of Medicine in 2025.

The final screen also explains that the PSA test has benefits and drawbacks, such as false alarms and finding cancers that would never cause harm, so the decision on testing is made together with a doctor. The game does not replace a conversation with a doctor; it encourages one.

Play the game

The game is available at https://pou-cakovec.hr/movember/

The game was developed within the CLEAR-PC project (Cancer Literacy Education and Awareness Resources for Prostate Care), co-funded by the EU4Health programme. More about the project: https://clearpc.eu/

Co-funded by the European Union under Grant Agreement No 101219353. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.